Clinical Trial Update: FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration [Phase 3]

View source ↗

Summary

This Phase 3 trial compares FCN-159 monotherapy with investigator's-choice chemotherapy for pediatric low-grade glioma with BRAF alterations; the study is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Chemotherapy by investigator's choice
• FCN-159

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Low-grade Glioma, Pediatric Low-grade Gliomas | Phase 3 | Status: NOT_YET_RECRUITING